Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript

Company Overview - Johnson & Johnson is represented by Dr. John Reed, Executive Vice President of Innovative Medicines R&D, who joined the company in 2023 after holding leadership positions at Sanofi and Roche [2]. Regulatory Environment - The company has reported that, despite significant changes in the FDA and HHS leadership, all PDUFA dates and regulatory deadlines have been met on schedule, indicating effective management of the regulatory process [5].